Dr. Julie K Derosa, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Neal Ave, Marion Center, PA 15759 Phone: 724-397-5571 Fax: 724-397-2800 |
Joseph Lindsay Parks, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 100 Neal Ave, Marion Center, PA 15759 Phone: 724-397-5571 Fax: 724-397-2800 |
Neil A Jacobson, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Neal Ave, Marion Center, PA 15759 Phone: 724-397-5571 Fax: 724-397-2800 |
News Archive
A group of researchers led by Johns Hopkins scientists say they have identified a genetic marker that may be associated with the development of obsessive-compulsive disorder (OCD), whose causes and mechanisms are among the least understood among mental illnesses.
A new study published on the preprint server bioRxiv* in September 2020 reports the use of artificial intelligence (AI) to identify an invariant or universal host immune response found in all viral pandemics so far. The association of this response with severe COVID-19 phenotypes indicates a new understanding of the human immune response in viral pandemics.
GE Healthcare today announced the FDA-cleared CARESCAPEā¢ Monitor B850, which provides caregivers with a unique level of integration between patient monitoring data and hospital information systems. Unlike traditional patient monitors, CARESCAPE Monitor B850 directly links hospital networks, electronic medical records (EMRs), diagnostic images, lab results and third-party devices with real-time patient monitoring data, to support efficient clinical decision-making.
Ultrasound scans might be most familiar for getting a peek at a developing fetus, but the technology could also be used to treat cancer. A partnership between UC Davis, Siemens Medical Systems and ImaRx Inc., funded by a National Cancer Institute grant, will study ways to deliver drugs to tumors using focused ultrasound.
Treatment with the anti-hypertensive drug valsartan (Diovan) led to a modest reduction in the development of type 2 diabetes but did not significantly reduce cardiovascular events in patients with impaired glucose tolerance, according to researchers at Duke University Medical Center and the University of Oxford. They jointly reported results at the American College of Cardiology meeting today from the world's first study designed to find ways to control the progression to diabetes and cardiovascular disease in people at risk.
› Verified 7 days ago